Ryan White Clinics for 340B Access yesterday criticized drug manufacturer Gilead Sciences for sponsoring a study that said it is unclear if patients of Ryan White clinics and other 340B grantee covered entities benefit from the drug margin these entities
…
Drug manufacturers often observe that a growing share of their take from gross sales goes to middlemen and others in the form of rebates and discounts. A term has been coined to describe the phenomenon: the gross-to-net bubble (the difference
…
Biopharmaceutical manufacturer Exelixis said today it is extending its conditions on 340B pricing to contract pharmacies that are wholly owned or under common ownership with a hospital covered entity. The change is effective June 26.
Exelixis announced the change in
…
Drug manufacturer Teva today became the 23rd drug manufacturer to impose conditions on 340B pricing involving delivery to contract pharmacies.
Covered entities reported getting Teva’s notice by email around 1:00 p.m. Eastern. It said effective July 5:
Federal Medicare drug price negotiation “is tantamount to extortion” and must be struck down as unconstitutional, drug manufacturer Merck told a federal district court yesterday.
Merck on Tuesday became the first drug maker to sue to stop the federal government
…
The U.S. Health Resources and Services Administration yesterday posted notices of refunds for 340B overcharges from drug manufacturers Lilly, Novo Nordisk, and Neurocrine and a notice from Amneal about product NDC changes.
Lilly
Lilly’s May 30 notice covers purchases
…
ASAP 340B, the group that drug manufacturers and community health centers formed to advance a joint 340B reform agenda, recently released a two-page explainer on how their plan would change the 340B patient definition. Under it, fewer drugs prescribed at
…
Drug manufacturer Merck is paying refunds for overcharges on 340B drugs purchased during the first two quarters of 2020.
Merck recently asked the U.S. Health Resources and Services Administration to post notices about its 340B ceiling price recalculations on the
…
Drug manufacturer Organon, the Merck spinoff with a focus on women’s health, today became the 22nd drug maker to impose conditions on 340B pricing involving delivery to contract pharmacies.
Covered entities began receiving an email from Organon around 3:00 p.m.
…*Sign up for news summaries and alerts from 340B Report